175 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
objective, having already treated 506,130 NCD patients in 31 countries as of the end of March 2024.
To support the set up and development of sustainable … , increasing the capacity of healthcare professionals for better management of NCDs and of supply chain actors, while building a sustainable procurement
6-K
EX-99.2
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
.
François-Xavier will join from Nestle, where he has been the CFO for more than 8 years, providing strong financial leadership and driving sustainable
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
of the Sustainable Markets Initiative (SMI) - Patient Care Pathways Working Group. In this context, Sanofi is working to decarbonize the delivery
6-K
EX-99.1
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
in our current product portfolio and the strength of our pipeline to deliver sustainable growth through 2030 and beyond. I could not be prouder
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
drivers in the quarter, exemplifying our successful strategy execution towards sustainable growth from innovative medicines. The underlying strength … affordable and sustainable access to diabetes care for 190,000 patients in LMICs by 2025.
Environment
Sanofi continues to invest to support its
6-K
EX-99.3
cvodq4d0 b0gz7q7
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
1uoc3rn 8m
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
kqvu uhfo
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
EX-99.3
vsgm5p2hk6
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.2
bgcd3ys9
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
75qzl0wh
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
6-K
EX-99.2
zv5fy8rpoqowwux4glk
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
6-K
EX-99.2
ujx7a636vlw3 xzfvt
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.1
yxwsgpnk nznjgf69
2 Dec 22
Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease
10:40am
6-K
EX-99.1
e08pewh0k
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
ftzpkaeq
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
s3l64mjhebgvb
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.1
am33ti dvh
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.1
lsp5vmx4
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.2
59bbtk9o00
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am